Offer - Urjas Oil for just ₹ 1 X
Ergagin 0.125 Tablet is a prescription medicine that is available as a Tablet. Post Delivery Bleeding are some of its major therapeutic uses.
Medical history of the patient along with age and gender determines the dosage of Ergagin 0.125 Tablet. Dosage also depends on the route of administration and your chief complaint for which the drug is prescribed. This information has been provided in detail in the dosage section.
The most common side effects of Ergagin 0.125 Tablet are Headache, Abdominal Pain, Hypertension. While these are the most often observed Ergagin 0.125 Tablet side effects, there are can be others also. These have been listed below. Normally, these side effects of Ergagin 0.125 Tablet are not long lasting and go away when the treatment is finished. However, if these continue for a longer time, consult your doctor right away.
Furthermore, you should know that effect of Ergagin 0.125 Tablet is Unknown for pregnant women and Unknown for women who are breastfeeding. Further, the section on Ergagin 0.125 Tablet related warnings talks about Ergagin 0.125 Tablet's effects on the liver, heart and kidney.
Individuals suffering from medical conditions like High Blood Pressure must refrain from the use of Ergagin 0.125 Tablet since this can cause severe adverse effects. Other conditions have been mentioned below in the Ergagin 0.125 Tablet contraindications section.
Additionally, Ergagin 0.125 Tablet may also adversely react with other medicines. See below for a complete list.
In addition to these precautions, you may also note that Ergagin 0.125 Tablet is safe while driving, and is is addictive in nature.
Ergagin 0.125 Tablet is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Is the use of Ergagin 0.125 Tablet safe for pregnant women?
The effects of Ergagin on pregnant women are unknown since no research has been done to ascertain it yet.
Is the use of Ergagin 0.125 Tablet safe during breastfeeding?
No research work has been carried out till date on effect of Ergagin on breastfeeding women. So it is not known whether taking Ergagin will cause side effects or not.
What is the effect of Ergagin 0.125 Tablet on the Kidneys?
Very few cases of side effects of Ergagin on kidney have been reported.
What is the effect of Ergagin 0.125 Tablet on the Liver?
Ergagin may cause harmful effects on liver. if you feel it's having any such effect, then stop taking this drug, and restart only on your doctor's advice.
What is the effect of Ergagin 0.125 Tablet on the Heart?
Effects of Ergagin on heart can be severe. It is not safe to use without doctor's advice.
If you are suffering from any of the following diseases, you should not take Ergagin 0.125 Tablet unless your doctor advises you to do so -
Is this Ergagin 0.125 Tablet habit forming or addictive?
Ergagin 0.125 Tablet does not cause addiction.
Is it safe to drive or operate heavy machinery when consuming?
Ergagin 0.125 Tablet will not make you feel sleepy or drowsy. So you drive or operate machinery safely.
Is it safe?
Yes, Ergagin 0.125 Tablet is safe but you must consult your doctor before taking it.
Is it able to treat mental disorders?
No, Ergagin 0.125 Tablet cannot treat any kind of mental disorder.
Interaction between Food and Ergagin 0.125 Tablet
There isn't any research available on the side effects of taking Ergagin 0.125 Tablet with food.
Interaction between Alcohol and Ergagin 0.125 Tablet
Due to lack of research, there is no information about the side effects of taking Ergagin 0.125 Tablet with alcohol.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Methergine® (methylergonovine maleate)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 331-332
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 837-839